Posted by Michael Wonder on 03 Mar 2022
ICER to assess treatments for obesity management
3 March 2022 - Report will be subject of New England CEPAC meeting in September 2022; draft scoping document open to public comment until 23 March 2022.
The Institute for Clinical and Economic Review announced today that it will assess the comparative clinical effectiveness and value of subcutaneous semaglutide (Wegovy, Novo Nordisk), phentermine/topiramate (Qsymia, Vivus Pharmaceuticals), liraglutide (Saxenda, Novo Nordisk), and naltrexone/bupropion (Contrave, Currax Pharma) for the treatment of obesity.
